Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
View Patent ↗The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to synergistic treatment over existing adenoviral therapy or traditional chemotherapy and radiation therapy.
1. A method for suppressing tumor growth in a mammal comprising:
administering to a mammal a synergistic combination of
a replication competent, target tumor cell-specific adenovirus, said adenovirus comprising an adenoviral gene essential for replication under transcriptional control of a prostate-specific antigen (PSA)-TRE wherein said target tumor cell-specific adenovirus results in virus replication-dependent cytolysis; and
at least one antineoplastic agent selected from the group consisting of paclitaxel and docetaxel, in a combined dosage effective to substantially reduce the numbers of said targeted solid tumor cell population to a level more than additive when compared to administration of the adenovirus and antineoplastic agent alone, wherein said tumor growth in said mammal is suppressed.
2. The method according to claim 1 , wherein said adenovirus is administered by site-specific injection.
3. The method according to claim 1 , wherein said adenovirus is administered by intravenous injection.
4. The method according to claim 1 , wherein said adenoviral gene essential for replication is an adenoviral early gene.
5. The method of claim 4 , wherein the adenoviral early gene is E1A.
6. The method of claim 4 , wherein the adenoviral early gene is E1B.
7. The method of claim 6 , wherein E1B has a deletion of the 19-kDa region.
8. The method of claim 1 , wherein said at least one antineoplastic agent is paclitaxel.
9. The method of claim 1 , wherein said at least one antineoplastic agent is docetaxel.